Word

KALVISTA

Status

Registered

Status Code

700

Status Date

Tuesday, August 29, 2023

Serial Number

79351011

Registration Number

7147580

Registration Date

Tuesday, August 29, 2023

Mark Type

4000

Filing Date

Wednesday, July 20, 2022

Published for Opposition

Tuesday, June 13, 2023

Trademark Owner History

Kalvista Pharmaceuticals Limited - Original Registrant

Classifications

5 Pharmaceutical preparations for the treatment of ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of diabetic macular edema; pharmaceutical preparations for the treatment of angioedema; pharmaceutical preparations for the treatment of hereditary angioedema; pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders

44 Medical and healthcare services relating to ophthalmic diseases and disorders; medical and health care services relating to diabetic macular edema; medical and healthcare services relating to angioedema; medical and healthcare services relating to hereditary angioedema; medical and healthcare services relating to diseases and disorders mediated by the contact activation system; medical and healthcare services relating to plasma kallikrein or factor XIIa mediated diseases or disorders

10 Medical and surgical instruments and apparatus for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders; drug delivery devices for use in the treatment of ophthalmic diseases and disorders, diabetic macular edema, angioedema, hereditary angioedema, diseases and disorders mediated by the contact activation system, and plasma kallikrein or factor XIIa mediated diseases or disorders

42 Drug discovery services relating to ophthalmic diseases and disorders; drug discovery services relating to diabetic macular edema; drug discovery services relating to angioedema; drug discovery services relating to hereditary angioedema; drug discovery services relating to diseases and disorders mediated by the contact activation system; drug discovery services relating to plasma kallikrein or factor XIIa mediated diseases or disorders

Trademark Events

Oct 23, 2023

Notification Processed By Ib

Sep 29, 2023

Final Disposition Notice Sent To Ib

Sep 29, 2023

Final Disposition Processed

Sep 28, 2023

Grant Of Protection Created, To Be Sent To Ib

Aug 29, 2023

Registered-Principal Register

Jun 13, 2023

Published For Opposition

May 24, 2023

Notice Of Publication

May 6, 2023

Approved For Pub - Principal Register

May 5, 2023

Assigned To Examiner

Oct 4, 2022

Application Filing Receipt Mailed

Sep 30, 2022

New Application Office Supplied Data Entered

Sep 29, 2022

Sn Assigned For Sect 66a Appl From Ib